Opinion|Videos|January 16, 2025
Advancements, Unmet Needs, and Future Trends in the Treatment of NMIBC
Author(s)Mark D. Tyson II, M.D., M.P.H.
A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing treatment toxicity, while expressing optimism about emerging trends in combination therapies, novel delivery systems, and personalized medicine approaches based on molecular profiling.
Advertisement
- What are some unmet needs in the treatment landscape of NMIBC that investigational and approved agents still haven’t addressed?
- What advancements and future trends are you looking forward to in the field, considering the various MOAs of investigational agents?
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
enGene expects to initiate a BLA submission by the end of 2026.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
5